Hematological Malignancies In the News

Jessica Appel | City of Hope

Diagnosed with an aggressive form of leukemia, Jessica Appel knew that her time was running out. Still, her story has a bittersweet ending, thanks to the many City of Hope employees on her care team who did everything they could to allow her to pass away on her own terms.


Amanda Salas Hero | City of Hope

Entertainment reporter Amanda Salas, 34, is undergoing six grueling rounds of chemotherapy at City of Hope to treat her rare form of non-Hodgkin's lymphoma. But she refuses to let it get her down.


HPV cells

HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.


Breakthroughs - prostate cancer clinical trial

In this phase 1 trial, the safety and tolerability of autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes are studied in adult patients with PSCA+ metastatic castration-resistant prostate cancer.


Saul Priceman | City of Hope

Saul Priceman, Ph.D., and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.


News Image

Saul Priceman, Ph.D., City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received an award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

News Image

City of Hope researchers found that “turning off” the BCL6 protein and using the small molecule ABT-199 eliminated drug resistance in mouse models that had a subtype of B cell acute lymphoblastic leukemia.

Caitlin Buchanon Small | City of Hope

Diagnosed with a rare, fast-growing blood cancer and ineligible for a lifesaving stem cell transplant after failing chemotherapy, treatment with a breakthrough CAR T drug called Yescarta was Caitlin Buchanan's best hope for survival.


Nadia Carlesso, M.D. - Profile Photo

Inspiration came early to Nadia Carlesso, M.D., Ph.D., associate director of basic research in the Gehr Family Center for Leukemia Research at City of Hope.


Tyler Routh | City of Hope

Tyler Routh is one of 13 leukemia patients who had a remarkable recovery after participating in Dr. Samer Khaled’s CAR T trial.


Ammar Chaudhry

The dynamic young founder and director of City of Hope’s Precision Imaging Lab, Ammar Chaudhry, M.D., is one of the first recipients of the new ORIEN NOVA Award. The $1 million grant will fund research for his breakthrough approach to cancer imaging and diagnosis.


Ammar Chaudhry

The dynamic young founder and director of City of Hope’s Precision Imaging Lab, Ammar Chaudhry, M.D., is one of the first recipients of the new ORIEN NOVA Award. The $1 million grant will fund research for his breakthrough approach to cancer imaging and diagnosis.


Jianjun Chen

Dr. Jianjun Chen was recently named the Simms/Mann Family Foundation Chair in Systems Biology. Chen was recognized with the endowment for his leading-edge cancer research that is founded in personalized, gene-based medicine.


News Image

Study results will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Rosenzweig-Michael

A City of Hope scientist believes the solution to the rare disease amyloidosis may be found in one of the most exciting new frontiers of immunotherapy, chimeric antigen receptor T cell therapy.


News Image

City of Hope is now enrolling patients with multiple myeloma whose disease has relapsed, or is treatment-resistant, for a first-of-its kind chimeric antigen receptor (CAR) T cell therapy trial. It will also manufacture CAR T cells in its own laboratories.

CIRM Annual Symposium of the Alpha Stem Cell Clinics Network

City of Hope’s bone marrow transplant program recently performed the procedure on its 15,000th patient. Today, age is no longer a barrier to transplant.


Al Malki-Monzr

City of Hope doctors have performed more than 250 haploidentical stem cell transplants in the last five years. They are giving more and more patients a new treatment option.


test tubes

City of Hope’s clinical trials program is special because it was built with the same core values as the institution itself: an emphasis on leading-edge medicine, compassionate care, rapid bench-to-bedside research and always putting the patient first.


Zeng-Defu

Scientist Defu Zeng is tackling graft-versus-host disease, a common side effect of bone marrow transplants, taking several tacks that include modulating T cells and fine-tuning specific proteins and antibodies.


breakthroughs - aids

Where in the early days of the HIV epidemic the idea of stem cell transplants for HIV patients with cancer was considered crazy, the procedure is now commonly performed.


Steven Rosen

Provost and Chief Scientific Officer Steven T. Rosen, M.D., the Irell & Manella Cancer Center Director’s Distinguished Chair, has been inducted as a member of the Association of American Physicians (AAP). Membership to the AAP is bestowed upon those physicians who indicate a "pre-eminence and the highest caliber of physician-led science accomplishments and scientific leadership."


AML | City of Hope

City of Hope opens recruitment for a phase I/II dose-finding study of novel agent 8-chloro-adenosine in patients with relapsed/refractory acute myeloid leukemia.


Blood Cancer | City of Hope

City of Hope is now enrolling relapsed/refractory multiple myeloma patients for a first-of-its kind chimeric antigen receptor T cell therapy phase I trial.


Christiane Querfeld, M.D., Ph.D.

City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.